Lymphoma, Mantle-Cell - 25 Studies Found
| Terminated |
: Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) : Lymphoma, Mantle-Cell : 2015-05-23 : Drug: Copanlisib (BAY80-6946) Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). A |
| Active, not recruiting |
: Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma :
|
| Active, not recruiting |
: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) :
|
| Active, not recruiting |
: EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma :
|
| Active, not recruiting |
: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2011-03-24 :
|
| Completed |
: Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2007-12-19 : Drug: modified Hyper-CVAD rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorub |
| Completed |
: Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2007-12-19 :
|
| Active, not recruiting |
: Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) : Mantle Cell Lymphoma : 2011-08-16 :
|
| Terminated |
: A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2009-02-12 : Drug: P276-00 P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 m |
| Active, not recruiting |
: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma : CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma : 2013-08-23 : Drug: rituximab |